Table 1.

Susceptibility testing of the K. pneumoniae isolates

	K. pneumoniae, blood culture, admission		K. pneumoniae, blood culture, hospital day 32
	MIC (mg/L)	interpretation	MIC (mg/L)	interpretation
VITEK®2 GN74
amikacin	≥64	R	≥64	R
ampicillin/sulbactam	≥32/16	R	≥32/16	R
aztreonam	≥64	R	≥64	R
cefazolin	≥64	R	≥64	R
cefepime	≥64	R	≥64	R
cefoxitin	≥64	R	≥64	R
ceftazidime	≥64	R	≥64	R
ceftriaxone	≥64	R	≥64	R
gentamicin	≥16	R	≥16	R
levofloxacin	≥8	R	≥8	R
meropenem	≥16	R	≥16	R
piperacillin/tazobactam	≥128/4	R	≥128/4	R
tobramycin	≥16	R	≥16	R
trimethoprim/sulfamethoxazole	≥16/304	R	≥16/304	R
Gradient diffusion
ceftazidime/avibactam	≥256	R	≥256	R
ceftolozane/tazobactam	≥256	R	≥256	R
meropenem/vaborbactam	≥256	R	24a	R
tigecyclineb	1.5	S	4	I
Disc diffusion
cefiderocol	18 mm	S
PAP testing
cefiderocol	≥32	HR	≥32	HR
aztreonam	≥64	R	≥64	R
ceftazidime/avibactam	≥64/4	R	≥64/4	R
aztreonam/avibactam	4/4	S	4/4	S

S, susceptible; I, intermediate; R, resistant; HR, heteroresistant; PAP, population analysis profiling.

Interpretations reported using CLSI breakpoints.

^aTrue MIC reported.

^bTigecycline is reported using FDA breakpoints.